Unilateral Bevacizumab for Bilateral Diabetic Macular Edema
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The endothelial growth factor (VEGF), has been implied in the genesis of diverse Neovascular
disease. In the industrialized and developing countries, the main cause of blindness is the
diabetic retinopathy. Bevacizumab (Avastin, genentech, Inc., San Francisco, California, the
USA) is a drug.In the last years its use "off-label", in ophthalmology field, has become
popular. This is due to its proven safeness and effectiveness for the treatment of diverse
ocular diseases. A lot has been speculated about the systemic absorption of Bevacizumab. It
is for that reason that the objective of this study is the systematic and random revision of
the fellows eyes, of the patients programmed for the intravitreal administration of
Bevacizumab, with bilateral macular edema. In such a way that the therapeutic value in the
fellow eye of bevacizumab can be determined